Charles Berkman, general counsel for Ligand Pharmaceuticals, left, and Hayden Trubitt, a shareholder in Stradling’s corporate practice group, right.
Being flexible while having a healthy appetite for risk appears to be paying off for Ligand Pharmaceuticals Inc., a San Diego-based firm that licenses and supplies Captisol, a crucial ingredient in experimental COVID-19 treatment drug remdesivir.
“Lawyers, in my personal view and to over-generalize, can be a little too risk-averse,” said Ligand’s longtime general counsel, Charles Berkman.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
